OncoMatch/Clinical Trials/NCT06134388
Sulfasalazine in Patients With Metastatic Colorectal Cancer
Is NCT06134388 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Sulfasalazine for metastatic colorectal cancer.
Treatment: Sulfasalazine — The aim of this study is to evaluate the potential efficacy and safety of sulfasalazine in patients with metastatic colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
hemoglobin, erythrocytes, platelets, leukocytes and ANC < grade 2 according to NCI-CTCAE v 5.0
Kidney function
eCrCl, SCr < grade 2 according to NCI-CTCAE v 5.0
Liver function
ALT and AST < grade 2 according to NCI-CTCAE v 5.0
Adequate liver function (ALT and AST < grade 2) according to NCI-CTCAE v 5.0; Adequate renal function (eCrCl, SCr < grade 2) according to NCI-CTCAE v 5.0; Adequate hematological parameters (hemoglobin, erythrocytes, platelets, leukocytes and ANC < grade 2 according to NCI-CTCAE v 5.0)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify